Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: Go-Gold, TheHungryHippo, BluSkies, GoldenMind
Search This Board: 
Last Post: 11/20/2017 8:40:58 AM - Followers: 794 - Board type: Free - Posts Today: 2


US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director



About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here:  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here:

USRM - Daily Candlesticks


Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: Quarterly Report (10-q) 11/07/2017 04:04:52 PM
USRM News: Current Report Filing (8-k) 09/13/2017 09:01:32 AM
USRM News: Initial Statement of Beneficial Ownership (3) 09/01/2017 04:06:18 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/01/2017 04:04:29 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/01/2017 04:02:44 PM
#83879  Sticky Note USRMSTRONG!!! stem cells have been an insider thing..... rocketRider 11/18/17 12:11:59 PM
#83060  Sticky Note $USRM UPDATE as of November 8th, 2017 per GoldenMind 11/08/17 08:48:30 AM
#79439  Sticky Note BOARD WARNING: Please Read IH Geek [Dave] 09/14/17 12:53:48 PM
#78232  Sticky Note Official response to FDA Warning Letter. Deal McMogulson 08/29/17 02:42:32 PM
#83928   So you deny the efficacy of any of Cryptofan 11/20/17 08:40:58 AM
#83927   GM USRM groupies: Zues 11/20/17 08:09:11 AM
#83926   Rmat would bring traders back for sure. However Afterhoursearnings3 11/19/17 09:08:00 PM
#83922   USRMSTRONG!! rocketRider 11/19/17 01:15:30 PM
#83920   Well Said$$$ Sagemaker1 11/19/17 12:43:45 PM
#83919   “And we intend to follow those standards as Rinkydink 11/19/17 12:09:22 PM
#83918   Per CSO Rinkydink 11/19/17 12:03:31 PM
#83917   You may very well be right Doc. Maybe Deal McMogulson 11/19/17 11:58:22 AM
#83916   If I'm not mistaken, I don't believe they docprep 11/19/17 11:45:46 AM
#83914   RTT doesn't truly maximize stem cell therapy potential docprep 11/19/17 11:40:11 AM
#83913   CEO STATES MARCH 2017 RMAT WOAZA$$$ Sagemaker1 11/19/17 11:30:39 AM
#83912   They said that because with unknown guidelines, it Deal McMogulson 11/19/17 11:11:37 AM
#83911   Quote LOL, "You should read the past news. Hornet Driver 11/19/17 11:11:10 AM
#83910   I thought they said they would stop putting Cdizz123 11/19/17 11:07:18 AM
#83909   You should read the past news. USRM stated sdave2002 11/19/17 10:55:02 AM
#83906   “We’re at the beginning of a paradigm change MyzStreet 11/19/17 10:10:02 AM
#83904   One dollar tomorrow ! Minus 40% I mean Cdizz123 11/19/17 08:31:03 AM
#83903   Are they still perusing RMAT? I thought they BluSkies 11/19/17 07:34:46 AM
#83902   I would be shocked if the company doesn’t Deal McMogulson 11/18/17 11:11:36 PM
#83901   Anything is possible... Greennewlife 11/18/17 11:11:22 PM
#83900   Exactly ! Quite frankly and excuse my French Cdizz123 11/18/17 11:05:40 PM
#83899   That was a sincere question. No sarcasm attached Deal McMogulson 11/18/17 11:00:10 PM
#83898   Thanks for saying that, not sure if sarcasm Cdizz123 11/18/17 10:55:40 PM
#83897   Gene therapy... yay tamtam84 11/18/17 10:44:33 PM
#83896   I LOVE THIS ... tamtam84 11/18/17 10:40:35 PM
#83895   CDizz, what’re you waiting to hear? You’ve been Deal McMogulson 11/18/17 10:35:02 PM
#83894   tldr GetRichorGetHighTryn 11/18/17 09:30:02 PM
#83893   WOWZA After 15 years with SI joint issues, KRex0969 11/18/17 09:09:53 PM
#83892   No brainer and penny stocks. Does not compute Cdizz123 11/18/17 08:47:38 PM
#83891   You love it because he’s saying what you Cdizz123 11/18/17 08:41:35 PM
#83890   Good post Xpecht. Lonewolf1 11/18/17 07:21:23 PM
#83889   Quote NO LOL, "No we have to 3 Hornet Driver 11/18/17 06:48:57 PM
#83888   Article: USCC, "MORE EGREGIOUS THAN IMAGINED"...wowza ! Hornet Driver 11/18/17 06:25:48 PM
#83887   Don’t you think this is the time big MyzStreet 11/18/17 05:53:37 PM
#83886   Much respect docprep 11/18/17 05:50:43 PM
#83885   Good post docprep 11/18/17 05:48:26 PM
#83884   When the guidelines were released I took the Xpecht 11/18/17 05:09:05 PM
#83883   This is fantastic news Afterhoursearnings3 11/18/17 04:56:13 PM
#83882   Moderator. Sticky this please TruthSpeaker12 11/18/17 01:35:59 PM
#83881   I love you rocket rider ! Usrm FTW !!!$$$ Joeymc77 11/18/17 12:36:51 PM
#83880   USRM - not bad As of November 7th, BluSkies 11/18/17 12:35:40 PM
#83879   USRMSTRONG!!! stem cells have been an insider thing..... rocketRider 11/18/17 12:11:59 PM
#83878   1. I believe we will have an announcement StemCellJunkie 11/18/17 11:58:32 AM
#83877   MONEY STATEMENT RIGHT HERE :: tamtam84 11/18/17 10:39:51 AM
#83876   The number of FDA approved treatments will skyrocket MyzStreet 11/18/17 10:17:13 AM
#83875   Anxiously awaiting USRM update on new FDA guidelines. joelew25 11/18/17 09:01:37 AM
#83871   No we have to 3 years of no docprep 11/17/17 08:48:13 PM
#83870   So we have 3 more years of stagnant Cdizz123 11/17/17 08:39:47 PM
#83869   The FDA guidelines open the door for good news...... TruthSpeaker12 11/17/17 08:06:29 PM
#83868   nice Truth. I agree we got a lot Rinkydink 11/17/17 07:07:26 PM